Atossa Therapeutics (ATOS)
Develops oral (Z)-endoxifen for breast cancer and selected rare diseases.
$2.22
vs last close−0.04 (−1.77%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 14.94% | 1.49M shares | |
|---|---|---|---|
| 33 holders · as of Jun 30, 2026 | |||
| Insiders | 2.14% | 213.4K shares | |
| 8 holders · as of May 14, 2026 | |||
| Other | 82.92% | 8.28M shares | |
| remainder | |||
9.98M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
33 holders · 1.49M shares · 5 new positions · 14 increased · 9 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 361.7K | 3.62% | +12.7K | Aug 13, 2026 |
| Ameriprise Financial Inc | 258.2K | 2.59% | +3.1K | Aug 14, 2026 |
| BlackRock, Inc. | 164.4K | 1.65% | +31.2K | Aug 7, 2026 |
| Aster Capital Management (Difc) Ltd | 144.9K | 1.45% | +144.9Knew | Aug 13, 2026 |
| Renaissance Technologies LLC | 132.0K | 1.32% | +23.0K | Aug 13, 2026 |
| Geode Capital Management, LLC | 92.4K | 0.93% | −4.7K | Aug 12, 2026 |
| UBS Group AG | 82.6K | 0.83% | −9.4K | Aug 13, 2026 |
| Jane Street Group, LLC | 56.6K | 0.57% | +56.6Knew | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.70% | Nov 8, 2024 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.